Emcure Pharmaceuticals
add_icon

Emcure Pharmaceuticals

1,845.90
-9.40
(-0.51%)
Market Cap
35,009.26 Cr
PE Ratio
34.56
Volume
1,14,806.00
Day High - Low
1,885.00 - 1,835.00
52W High-Low
2,048.00 - 1,260.00
hide
Key Fundamentals
Add Ratio
split_icon_default
Market Cap
35,009.26 Cr
EPS
48.77
PE Ratio
34.56
PB Ratio
7.11
Book Value
260.97
EBITDA
1,833.20
Dividend Yield
0.19 %
Industry
Healthcare
Return on Equity
15.24
Debt to Equity
0.45
Analyst Rating and Forecast
- By Refinitiv from8 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy
Buy+87.50 %
+87.50 %
Hold
Hold+12.50 %
+12.50 %
Sell
Sell0.0 %
0.0 %
Forecast For
Actual

Company News

View All News
Caret
neutral
Emcure Pharma to meet analysts and investors on Sep 412 hrs ago
Emcure Pharmaceuticals has scheduled a meeting with analysts and investors on September 4. The engagement signals the company's intent to communicate directly with the investment community.
neutral
Emcure Pharmaceuticals Limited has filed its Business Responsibility and Sustainability Report for FY26. The filing details environmental metrics, employee safety data, and governance disclosures as per SEBI regulations.
neutral
Emcure Pharmaceuticals has scheduled its 45th Annual General Meeting for September 21, 2026. The meeting will be held via video conferencing. Remote e-voting opens on September 18 and closes on September 20.
View more
Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
1,929.00
#1 4,62,831.72
38.73
#1 61,673.90
12.69
#1 11,565
26.53
50.68
9,165.00
2,43,301.95
83.91
11,067.00
13.95
2,568
65.50
69.96
4,965.50
1,88,871.66
87.83
13,886.20
20.34
2,138
3.28
51.80
1,167.80
1,17,508.01
25.24
27,657.90
17.64
5,026
-34.90
56.50
1,423.00
1,14,956.39
34.09
29,044.60
2.24
3,870
-39.18
46.47
1,861.60
1,00,499.70
94.50
6,867.80
22.01
890
#1 123.93
58.70
2,153.00
98,442.17
#1 17.94
29,038.90
#1 26.75
5,356
16.00
30.16
1,171.00
97,739.75
30.55
35,058.60
3.90
4,158
-69.10
44.37
2,356.50
97,322.50
47.92
14,636.40
14.85
1,938
29.13
40.51
1,683.30
96,853.36
26.21
34,145.20
5.56
3,503
25.21
61.10

Automatic Screeners on ScanX

Growth Rate
Revenue Growth
15.49 %
Net Income Growth
26.44 %
Cash Flow Change
-22.38 %
ROE
-9.82 %
ROCE
-1.72 %
EBITDA Margin (Avg.)
2.79 %

Quarterly Financial Results

Quarterly Financials
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Sept 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
1,571
1,664
1,697
1,783
1,839
2,038
1,967
2,121
2,104
2,273
2,365
2,484
2,583
Expenses
1,261
1,337
1,381
1,460
1,479
1,621
1,608
1,724
1,687
1,794
1,909
1,990
2,048
EBITDA
311
327
316
323
360
417
359
397
417
479
456
494
535
Operating Profit %
19 %
20 %
17 %
18 %
19 %
19 %
18 %
19 %
20 %
21 %
19 %
19 %
21 %
Depreciation
67
70
84
91
94
97
97
97
100
105
105
106
110
Interest
52
59
61
66
59
46
32
39
27
33
38
46
32
Profit Before Tax
191
198
171
167
207
273
230
261
291
341
314
341
394
Tax
50
52
51
46
55
72
74
63
76
90
82
97
101
Net Profit
141
146
120
121
153
202
156
197
215
251
231
244
293
EPS in ₹
7.21
7.70
6.27
6.36
7.95
10.23
8.12
9.97
10.92
12.85
12.16
12.84
15.50

Balance Sheet

Balance Sheet
2018
2019
2020
2021
2022
2023
2024
2025
Total Assets
5,247
5,644
6,004
6,807
6,064
6,673
7,806
8,233
Fixed Assets
2,049
2,247
2,382
2,188
2,044
2,147
3,125
3,197
Current Assets
2,335
2,453
2,703
3,718
3,424
3,836
4,260
4,556
Capital Work in Progress
531
581
485
302
320
411
159
177
Investments
0
0
0
0
25
25
318
95
Other Assets
2,667
2,817
3,137
4,318
3,674
4,089
4,204
4,763
Total Equity & Liabilities
5,247
5,644
6,004
6,807
6,064
6,673
7,806
8,233
Current Liabilities
2,336
2,543
2,920
3,408
2,965
3,019
3,211
2,668
Non Current Liabilities
1,157
1,201
1,100
1,031
985
1,004
1,474
923
Total Equity
1,755
1,900
1,984
2,368
2,114
2,650
3,122
4,642
Reserve & Surplus
1,520
1,654
1,731
2,092
1,807
2,320
2,771
4,257
Share Capital
181
181
181
181
181
181
181
190

Cash Flow

Cash Flow
2019
2020
2021
2022
2023
2024
2025
Net Cash Flow
-700
32
259
42
134
219
-58
Investing Activities
-409
-168
-257
-575
-468
-715
-96
Operating Activities
444
500
704
768
747
1,097
852
Financing Activities
-735
-301
-189
-152
-145
-164
-814

Share Holding

% Holding
Jul 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Sept 2025
Dec 2025
Mar 2026
Jun 2026
Promoter
78.08 %
78.08 %
77.94 %
77.92 %
77.91 %
77.88 %
77.87 %
77.87 %
77.83 %
FIIs
1.76 %
2.91 %
3.05 %
3.07 %
2.86 %
3.29 %
3.59 %
3.35 %
4.88 %
DIIs
3.34 %
3.96 %
3.87 %
3.44 %
2.84 %
4.37 %
6.10 %
6.10 %
8.46 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
7.73 %
5.00 %
5.14 %
5.51 %
5.95 %
6.24 %
6.46 %
6.46 %
6.45 %
Others
9.10 %
10.04 %
10.00 %
10.06 %
10.44 %
8.22 %
5.98 %
6.22 %
2.38 %
No of Share Holders
4,98,006
1,52,914
1,43,449
1,39,671
1,33,549
1,26,169
1,18,863
1,22,189
1,24,991

Dividend History

Annual Cash Flows 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Dividend Per Share (₹) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 2 3 0.00
Dividend Yield (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.19 0.19 0.00

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
21 Sept 2026 ANNUAL GENERAL MEETING Annual General Meeting
NA
21 Sept 2026 1,878.40 1,855.30
04 Sept 2026 DIVIDEND Dividend
₹ 3.60 /share
04 Sept 2026 1,785.15 1,855.30
07 Nov 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
07 Nov 2024 1,406.40 1,444.25
06 Feb 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
06 Feb 2025 1,345.75 1,249.80
22 May 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
22 May 2025 1,036.35 1,073.60
07 Aug 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
07 Aug 2025 1,405.55 1,421.25
14 Aug 2025 DIVIDEND Dividend
₹ 3.00 /share
14 Aug 2025 1,073.60 1,453.80
28 Aug 2025 ANNUAL GENERAL MEETING Annual General Meeting
NA
28 Aug 2025 1,408.15 1,468.60
11 Nov 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
11 Nov 2025 1,318.00 1,426.60
04 Feb 2026 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
04 Feb 2026 1,557.90 1,505.75
05 May 2026 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
05 May 2026 1,636.30 1,785.15
06 Aug 2026 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
06 Aug 2026 1,810.10 1,959.00

Announcements

Intimation Under Regulations 30 And 36(1)(B) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 201512 hrs ago
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation13 hrs ago
Announcement under Regulation 30 (LODR)-Credit Rating13 hrs ago
Announcement under Regulation 30 (LODR)-Newspaper Publication3 days ago
Business Responsibility and Sustainability Reporting (BRSR)4 days ago
Notice Of The 45Th Annual General Meeting4 days ago
Reg. 34 (1) Annual Report.4 days ago
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS7 days ago
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeAug 12, 2026
Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Aug 08, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 07, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 07, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 07, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 07, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 07, 2026
Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 07, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeAug 06, 2026
Intimation Of Date Of The 45Th Annual General Meeting And Record DateAug 06, 2026
Announcement under Regulation 30 (LODR)-Change in ManagementAug 06, 2026
Announcement under Regulation 30 (LODR)-Investor PresentationAug 06, 2026
Unaudited Financial Results (Standalone And Consolidated) For The Quarter Ended June 30 2026Aug 06, 2026
Board Meeting Outcome for Outcome Of Board Meeting Held On August 06 2026Aug 06, 2026
Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Update On Completion Of Acquisition Of Shares Of Gennova Biopharmaceuticals Limited. Jul 22, 2026
Announcement under Regulation 30 (LODR)-Change in ManagementJul 21, 2026
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJul 20, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJul 15, 2026
Board Meeting Intimation for Board Meeting Intimation For Approval Of Unaudited Financial Results (Standalone And Consolidated) For The Quarter Ended June 30 2026Jul 15, 2026
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJul 13, 2026
Announcement under Regulation 30 (LODR)-AcquisitionJul 13, 2026
Announcement under Regulation 30 (LODR)-RestructuringJul 11, 2026
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 07, 2026
Announcement under Regulation 30 (LODR)-AcquisitionJul 03, 2026
Announcement under Regulation 30 (LODR)-Change in ManagementJun 30, 2026
Closure of Trading WindowJun 29, 2026
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSJun 19, 2026
Announcement under Regulation 30 (LODR)-Investor PresentationJun 12, 2026
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSMay 27, 2026
Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 27, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 20, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 20, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 20, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 20, 2026
Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - US FDA Inspection At Our Formulations Facility Located At Sanand Ahmedabad Gujarat India.May 16, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 11, 2026
Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - ESG RatingMay 08, 2026
Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 06, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 05, 2026
Announcement under Regulation 30 (LODR)-Change in ManagementMay 05, 2026
Announcement under Regulation 30 (LODR)-Change in ManagementMay 05, 2026
Announcement under Regulation 30 (LODR)-Investor PresentationMay 05, 2026

Mutual Fund Holdings

Funding HouseCurrent Holding %1M Change1M Change %3M Change %Last 6M Trend
Baroda BNP Paribas Health and Wellness Fund Direct-Growth
2.46%
-43425
-1.14%
-0.92%
Samco Small Cap Fund Direct-Growth
2.17%
18903
2.17%
2.17%
JioBlackRock Sector Rotation Fund Direct-Growth
0.00%
-472
-0.05%
0.00%
JioBlackRock Nifty Smallcap 250 Index Fund Direct-Growth
0.31%
297
0.02%
0.03%
Zerodha Nifty MidSmallcap400 50:50 Index Fund Direct-Growth
0.16%
22
0.01%
0.03%
DSP Nifty Smallcap 250 Index Fund Direct-Growth
0.31%
18
0.01%
0.02%
UTI Nifty500 Shariah Index Fund Direct-Growth
0.11%
-4
0.00%
0.01%
Motilal Oswal BSE 1000 Index Fund Direct-Growth
0.03%
-2
0.00%
0.00%
Navi Nifty MidSmallcap 400 Index Fund Direct-Growth
0.11%
-1
0.01%
0.01%
Groww Aggressive Hybrid Fund Direct-Growth
0.00%
0
0.00%
0.00%
HDFC Balanced Advantage Fund Direct-Growth
0.01%
0
0.00%
0.00%
Aditya Birla Sun Life Small Cap Fund Direct-Growth
1.32%
0
0.00%
0.16%
Angel One Nifty Total Market Index Fund Direct-Growth
0.03%
0
0.00%
0.00%
Axis Balanced Advantage Fund Direct-Growth
0.00%
0
0.00%
0.00%
Axis Business Cycles Fund Direct-Growth
0.00%
0
0.00%
0.00%
Axis Equity Savings Fund Direct-Growth
0.46%
0
0.00%
0.02%
Axis Multi Asset Allocation Direct Plan-Growth
0.48%
0
0.00%
0.01%
Axis Nifty 500 Index Fund Direct-Growth
0.03%
0
0.00%
0.00%
HDFC BSE 500 Index Fund Direct-Growth
0.03%
0
0.00%
0.00%
Bajaj Finserv Healthcare Fund Direct-Growth
4.37%
0
0.00%
0.01%
Bandhan BSE Healthcare Index Fund Direct-Growth
0.42%
0
0.00%
0.02%
Bandhan Flexi Cap Fund Direct-Growth
0.00%
0
0.00%
0.00%
Bandhan Healthcare Fund Direct-Growth
0.00%
0
0.00%
0.00%
Bandhan Multi Asset Allocation Fund Direct-Growth
0.00%
0
0.00%
0.00%
Bandhan Multi Cap Fund Direct-Growth
0.00%
0
0.00%
0.00%

Technical Indicators

RSI(14)
Neutral
43.14
ATR(14)
Less Volatile
50.03
STOCH(9,6)
Neutral
23.83
STOCH RSI(14)
Oversold
16.84
MACD(12,26)
Bearish
-11.09
ADX(14)
Weak Trend
19.04
UO(9)
Bearish
35.87
ROC(12)
Downtrend And Accelerating
-7.68
WillR(14)
Oversold
-86.94

About Emcure Pharmaceuticals

Emcure Pharmaceuticals Limited is an Indian pharmaceutical company founded in 1981. It develops, manufactures, and globally markets pharmaceutical products across various therapeutic areas. The company operates 13 manufacturing facilities in India and has a presence in over 70 countries, with a strong focus on India, Europe, and Canada. Emcure specializes...more
Listing Date
10 Jul, 2024(2 Years, 1 Month, 23 Days)
Chairperson NameSATISH RAMANLAL MEHTA